Diagram showing why aspergillosis is often controlled rather than cured, including differences between ABPA and chronic pulmonary aspergillosis (CPA)

Can Aspergillosis Be Cured? Understanding Treatment, Control, and Long-Term Therapy

Last reviewed: April 2026


Key points

  • Aspergillosis is caused by fungi from the Aspergillus group.
  • Most people breathe in Aspergillus spores regularly without becoming ill.
  • In some people, damaged airways, lung cavities, mucus plugs, or immune responses allow the fungus or fungal material to persist.
  • Antifungal treatment may aim to cure, but in many cases the goal is long-term control.
  • Steroids can reduce harmful inflammation in allergic disease, but they can also reduce the body’s ability to clear fungus.

Table of contents


Overview

It is very common for people diagnosed with aspergillosis to feel worried when they read that others have been taking antifungal medication for months or even years.

This can lead to an understandable question:

“Does treatment actually work, or will I have this forever?”

The answer is more nuanced than a simple yes or no. Different forms of aspergillosis behave differently, and treatment goals vary depending on the condition.

Two of the most common conditions are:

Understanding this difference is key to understanding why treatment may continue for a long time.

If you would like a more detailed explanation of how these conditions are diagnosed and managed, see our guides to chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA).


Why breathing in spores does not usually cause disease

Aspergillus spores are present in the environment, including air, soil, compost, dust, and decaying vegetation. Most people breathe in small numbers of these spores regularly without becoming ill.

In healthy lungs, spores are usually cleared by the immune system and by the normal cleaning mechanisms of the airways.

This means:

  • Exposure to Aspergillus is common
  • Most exposure does not lead to disease
  • Aspergillosis usually develops only when there are additional risk factors, such as lung damage, mucus trapping, or altered immune responses

So it is not accurate to think of most patients as being “constantly reinfected”. A better way to think about it is that some lungs provide conditions where Aspergillus, or fungal material, can persist and continue to cause problems.


Why aspergillosis can be hard to clear

Aspergillosis can be difficult to clear for several reasons. These include the structure of the lungs, the biology of the fungus, limitations of drug penetration, and the way the immune system responds.

1. Damaged lung tissue can provide protected spaces

In CPA, Aspergillus often grows in areas of abnormal lung, such as cavities, scarred tissue, or areas affected by bronchiectasis.

These areas can act as protected spaces where the fungus is harder for the immune system and antifungal medicines to reach.

2. Thick mucus can trap fungus and fungal material

In airway diseases such as asthma, bronchiectasis, and ABPA, thick mucus can trap spores, hyphae, and fungal fragments.

This trapped material can continue to stimulate inflammation even when the fungus is not invading lung tissue.

3. Antifungal medicines may suppress rather than sterilise

Antifungal medications can reduce fungal activity and help prevent progression, but they may not always remove every trace of fungus from damaged lung spaces or mucus-filled airways.

For this reason, success is often measured by:

  • Improved symptoms
  • Stabilised weight and energy
  • Fewer flare-ups
  • Stable or improved scans
  • Prevention of further lung damage

Infection and ABPA: different reasons for persistence

Chronic pulmonary aspergillosis: persistence of infection

In chronic pulmonary aspergillosis, the problem is fungal growth in damaged lung tissue.

  • Lung cavities provide spaces where fungus can grow
  • Drug penetration may be limited
  • The immune system may not fully clear infection

Allergic bronchopulmonary aspergillosis: persistence of reaction

In ABPA, the main issue is an exaggerated immune response.

  • Mucus traps fungal material
  • Small amounts can trigger strong reactions
  • Inflammation leads to more mucus

Do steroids influence this?

Yes. Steroids can be helpful but must be used carefully.

In ABPA, they reduce inflammation but may also reduce fungal clearance.

In chronic infection, steroids can increase the risk of persistence or progression.

Monitoring and drug interactions are important during treatment.


Control vs cure: what is the goal?

For many people, the realistic goal is:

  • Stability rather than eradication
  • Reduced symptoms
  • Prevention of progression

 

Diagram showing why aspergillosis is often controlled rather than cured, including differences between ABPA and chronic pulmonary aspergillosis (CPA)
Aspergillosis is often managed as a long-term condition. This diagram shows why complete cure can be difficult and how treatment focuses on control.

Common antifungal treatments

  • Itraconazole
  • Voriconazole
  • Posaconazole

These treatments are selected based on individual factors and require monitoring.


Why don’t I hear many success stories?

People who improve often post less, while those still struggling are more visible in forums.


When to seek medical advice

  • Uncertainty about treatment
  • Side effects
  • Weight loss
  • Worsening symptoms

Common questions

Can aspergillosis be cured?

Sometimes, but often it is managed long-term.

Are people constantly reinfected?

No. Most people clear spores regularly without issue.

Why is ABPA difficult to treat?

Because of ongoing immune reactions and mucus trapping.


Further reading



Recurrent chest infections not responding to antibiotics infographic showing ABPA and CPA pathways

When ‘chest infections’ don’t respond: when to suspect ABPA or CPA (Clinical perspective)

Patients presenting with recurrent “chest infections” that do not respond to antibiotics are common in primary and secondary care. In a subset of these cases, the underlying cause may not be bacterial, but related to fungal disease or immune-mediated responses to Aspergillus.

This article summarises when to suspect allergic bronchopulmonary aspergillosis (ABPA) or chronic pulmonary aspergillosis (CPA), and how to move from repeated empirical treatment to a more structured diagnostic approach.


Key clinical message

Repeated antibiotic-treated exacerbations with limited response, particularly when symptoms improve with steroids and then relapse, should prompt reconsideration of the diagnosis.


When to suspect ABPA or CPA

Consider aspergillosis-related disease in patients with:

  • Recurrent “chest infections” with poor or inconsistent antibiotic response
  • Steroid-responsive symptoms with relapse on reduction or cessation
  • Persistent or unexplained radiological abnormalities
  • Underlying lung disease:
    • Asthma
    • Bronchiectasis
    • Chronic obstructive pulmonary disease (COPD)
    • Previous tuberculosis or lung damage
  • Raised or previously documented abnormalities in:
    • Total IgE
    • Eosinophils
    • Aspergillus-specific markers (if previously tested)

These features are not diagnostic in isolation but should raise suspicion when seen together.


ABPA vs CPA: clinical distinction

Feature ABPA CPA
Primary mechanism Immune-mediated (allergic) Chronic fungal infection
Typical background Asthma, bronchiectasis Structural lung disease, prior TB, COPD
Steroid response Often marked Variable (may improve symptoms but not disease)
Antibiotic response Limited Limited
Radiology Mucus plugging, bronchiectasis Cavities, fungal balls, fibrosis

Common pitfalls in practice

  • Repeated empirical antibiotics despite poor response
  • Short courses of steroids without a long-term management plan
  • Reliance on chest X-ray alone in persistent or atypical cases
  • Failure to recognise patterns across multiple consultations or admissions

These patterns can lead to prolonged diagnostic delay, which is well described in CPA and ABPA.


Suggested diagnostic approach

1. Reassess the working diagnosis

When standard treatment fails, explicitly reconsider whether the presentation remains consistent with bacterial infection.

2. Imaging

  • Escalate from chest X-ray to CT thorax where appropriate
  • Look for:
    • Cavitation
    • Fungal ball (aspergilloma)
    • Mucus plugging
    • Bronchiectasis

3. Blood tests

  • Total IgE
  • Eosinophil count
  • Aspergillus-specific IgE and IgG (where available)

4. Microbiology / further testing

Depending on context, consider sputum culture, fungal markers, or specialist input.


The steroid–relapse pattern

A common clinical scenario:

Exacerbation → steroids → improvement → relapse

This should raise suspicion of an underlying inflammatory or fungal-driven process rather than recurrent bacterial infection alone.


When to consider referral

Referral to a specialist centre (e.g. National Aspergillosis Centre, Manchester) may be appropriate where:

  • Diagnosis remains uncertain
  • Symptoms are persistent or progressive despite treatment
  • Antifungal therapy is being considered or not tolerated
  • Radiology suggests CPA or complex disease

Referral decisions should be made in the context of overall patient condition, comorbidities, and goals of care.


Why diagnosis is often delayed

  • Overlap with common respiratory conditions
  • Partial response to standard therapies
  • Fragmentation across care settings
  • Limited exposure to aspergillosis in routine practice

Recognising the pattern is often the key step in reducing delay.


Practical takeaways

  • If antibiotics are not working, reconsider the diagnosis
  • If steroids repeatedly improve symptoms, ask why
  • Use CT imaging to clarify persistent abnormalities
  • Aim for a clear, shared management plan

Guidelines and further reading

  • British Thoracic Society. Clinical Statement on Aspergillus-related chronic lung disease
  • ISHAM Working Group. Guidelines for ABPA diagnosis and management
  • Denning DW et al. Chronic pulmonary aspergillosis guidelines

Further professional resources


Aspergillosis.org – Information for healthcare professionals


This article is intended for educational purposes and should be interpreted in the context of individual clinical judgement.


AntifungalInteractions.org – A Specialist Resource for Safer Antifungal Treatment

Last reviewed: April 2026

Managing antifungal medications can be complex. Many antifungal drugs interact with other medicines, foods, and even supplements.
To support both patients and healthcare professionals, a dedicated resource is available:
AntifungalInteractions.org.


Key Points

  • A specialist database focused specifically on antifungal drug interactions
  • More detailed and targeted than general resources such as the British National Formulary (BNF)
  • Includes guidance designed for both healthcare professionals and patients
  • Regularly updated (typically several times per month)
  • Maintained by an experienced clinical pharmacist and prescriber
  • Owned and supported by the Fungal Infection Trust

What is AntifungalInteractions.org?

AntifungalInteractions.org is a dedicated online database designed to help users understand how antifungal medications interact with:

  • Other prescribed drugs
  • Over-the-counter medications
  • Herbal supplements
  • Certain foods and drinks

Unlike general drug reference tools, this resource focuses specifically on antifungal medicines, making it particularly useful for conditions such as aspergillosis, where treatment often involves long-term or complex therapy.


Why This Resource Matters

1. Antifungal drugs are complex

Common antifungal medications such as azoles (e.g. itraconazole, voriconazole, posaconazole) are known to interact with many other drugs.
These interactions can:

  • Increase side effects
  • Reduce treatment effectiveness
  • Require dose adjustments or monitoring

2. General resources may not go far enough

Widely used tools like the British National Formulary (BNF) are essential, but they are designed for broad use across all medicines.
AntifungalInteractions.org provides:

  • More detailed interaction explanations
  • Practical interpretation of risk
  • Condition-specific relevance

3. It supports informed discussions

The database is not a replacement for clinical advice, but it can help patients and clinicians:

  • Prepare for consultations
  • Understand potential risks
  • Ask more informed questions

Who Maintains the Database?

AntifungalInteractions.org is maintained by:

Saarah Niazi-Ali
MPharm, PG Cert (General Pharmacy Practice), PG Dip (Advanced Clinical Pharmacy Practice),
Independent Pharmacist Prescriber, Non-Medical Prescribing (Level 7), Final Medical Signatory

The database is updated frequently—typically 3–4 times per month, often on a weekly basis—ensuring that information remains current and clinically relevant.


Governance and Ownership

The resource is owned and supported by the Fungal Infection Trust, a UK-based organisation dedicated to improving the understanding, diagnosis, and treatment of fungal diseases.

This ensures that the database:

  • Remains focused on patient benefit
  • Is aligned with specialist fungal disease care
  • Supports both clinical practice and patient education

Who Is It For?

Patients and carers

  • To better understand their medications
  • To check for potential interactions
  • To support conversations with their clinical team

Healthcare professionals

  • Infectious disease specialists
  • Respiratory clinicians
  • Pharmacists
  • GPs managing complex patients

It is particularly valuable for clinicians managing conditions such as:

  • Chronic pulmonary aspergillosis (CPA)
  • Allergic bronchopulmonary aspergillosis (ABPA)
  • Other fungal infections requiring long-term antifungal therapy

How Does It Compare to Other Resources?

Feature AntifungalInteractions.org General Drug References (e.g. BNF)
Focus Antifungal-specific All medicines
Level of detail High (specialist) Moderate (broad coverage)
Patient-friendly explanations Yes Limited
Update frequency Frequent (monthly/weekly) Regular but broader scope

Important Notes for Patients

While this database is a valuable resource, it should be used appropriately:

  • Do not stop or change medication based on what you read
  • Always discuss concerns with your doctor, pharmacist, or specialist team
  • Use the information to support—not replace—medical advice

When to Seek Medical Advice

Contact your healthcare provider if you:

  • Start a new medication while on antifungal treatment
  • Experience new or worsening side effects
  • Are unsure whether a supplement or food is safe
  • Have been advised of a potential interaction

Summary

AntifungalInteractions.org is a highly valuable, specialist resource that fills an important gap in antifungal care.
Its combination of:

  • Expert clinical oversight
  • Frequent updates
  • Patient-accessible explanations
  • Specialist focus

makes it an important tool for both patients and healthcare professionals managing fungal disease.


Further Reading


Author & Review

Prepared for Aspergillosis patient and healthcare education.
Content aligned with UK specialist practice and reviewed for clarity and safety.


Aspergillosis and Diet: coping with weight loss, poor appetite, food avoidance and stomach symptoms

For: patients, carers, general practitioners, specialist nurses and other non-specialists


Key points

  • Eating difficulties are common in aspergillosis, especially in chronic pulmonary aspergillosis (CPA) and in people who also have other lung disease.
  • The problem is often not simply “poor appetite”. Breathlessness, cough, fatigue, reflux, nausea, altered taste and medicine side effects can all make eating difficult.
  • Some people gradually cut out more and more foods because eating feels uncomfortable or because they have been told certain foods are “bad” for lung symptoms.
  • For many patients, the main nutritional goal is not a “perfect” diet. It is getting enough energy, protein and fluids in ways that feel manageable.
  • “Little and often”, food fortification and nourishing drinks are often more realistic than trying to eat three large meals a day.
  • Ongoing weight loss, a very restricted diet, persistent nausea, reflux or difficulty eating most days should be discussed with a doctor, specialist team or dietitian.


Why diet can become a major problem in aspergillosis

Many people living with aspergillosis find that eating becomes much harder than it used to be. This is particularly important in chronic pulmonary aspergillosis (CPA), where weight loss, fatigue and general ill health are common features of the illness. In practical terms, the body may need more energy while the person is less able to eat comfortably.

Several problems can overlap:

  • Breathing takes more effort, which can increase energy needs.
  • Coughing or breathlessness can interrupt meals.
  • Tiredness can make shopping, cooking and eating feel like hard work.
  • Inflammation and chronic illness can reduce appetite and contribute to muscle loss.
  • Antifungal treatment and other medicines can cause nausea, altered taste, indigestion or poor appetite.
  • Reflux, bloating or early fullness may mean that even small meals feel uncomfortable.

For some patients this creates a vicious circle: eating becomes unpleasant, intake falls, weight drops, strength falls, and eating may then feel even more difficult.

Who is most affected?

Not every patient with aspergillosis has major nutritional problems, but some groups are more likely to struggle. This includes people with:

  • Chronic pulmonary aspergillosis (CPA)
  • pre-existing lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis or previous tuberculosis
  • long-term fatigue, breathlessness or coughing
  • persistent nausea or reflux symptoms
  • a history of recent unplanned weight loss
  • side effects from antifungal or other medicines
  • anxiety around eating because meals repeatedly trigger symptoms

Some people with allergic bronchopulmonary aspergillosis (ABPA) also report poor intake or nutritional difficulties, although the pattern may differ from CPA. In ABPA, steroid treatment, asthma burden, medicine effects and general symptom load may all influence diet.

How eating can become difficult

People often describe eating problems in ways that do not sound like a classic “nutrition” issue. They may say things like:

  • “I get full after a few mouthfuls.”
  • “I cannot face a proper meal.”
  • “Eating makes me cough.”
  • “I feel uncomfortable after food.”
  • “Some foods seem to sit badly.”
  • “I only eat a few safe foods now.”

These experiences are important. They suggest that the real problem may be a mixture of breathlessness, upper gastrointestinal symptoms, medicine effects and learned food avoidance, not simply a lack of willpower or poor food choices.

When eating shrinks into a “minimal diet”

Some patients end up eating very little, often because that feels safer or more manageable than trying to eat normally. A “minimal diet” may look like:

  • very small amounts of food only once or twice a day
  • mostly soft or liquid foods
  • reliance on tea, toast, soup or yoghurt
  • long gaps without eating
  • skipping meals because eating feels exhausting

This is understandable, but it can become a serious problem. Small intake over time may lead to:

  • weight loss
  • loss of muscle mass
  • greater weakness and fatigue
  • slower recovery from illness
  • reduced ability to cope with infections or treatment

If a patient is managing only tiny amounts of food, the first goal is often not to rebuild a “normal” diet immediately. It is to make intake easier, more comfortable and more nourishing.

Avoiding many food types

Another common pattern is gradual food restriction. Patients may stop eating several food groups because they believe these foods worsen mucus, cough, reflux, nausea or fungal disease.

Examples include avoiding:

  • dairy products
  • sweet foods
  • bread or dry foods
  • meat
  • acidic foods
  • foods linked in the mind to a previous bad episode

Sometimes there is a genuine reason for avoiding a particular food. For example, reflux may make acidic or very fatty foods uncomfortable, and a dry crumbly food may clearly trigger coughing. The difficulty is that repeated bad experiences can also lead to over-restriction, where more and more foods are cut out than is really necessary.

That can leave the diet low in calories, low in protein and very repetitive. In practice, the aim is usually to adapt foods rather than cut out whole food groups unless there is a clear reason to avoid them.

Could the stomach or gut be part of the problem?

Yes. This is often overlooked.

Some patients with aspergillosis describe symptoms that sound mainly digestive rather than respiratory, for example:

  • nausea
  • heartburn or reflux
  • bloating
  • feeling full very quickly
  • upper abdominal discomfort
  • reduced appetite after starting or changing medication
  • alternating diarrhoea and constipation

There are several possible reasons:

  • Medicine side effects, including antifungals
  • Gastro-oesophageal reflux disease (GORD), which can also worsen cough
  • reduced activity levels and chronic illness
  • constipation, especially when intake is poor or medicines contribute
  • co-existing gastrointestinal disease that is separate from aspergillosis

If eating repeatedly causes upper abdominal or chest discomfort, or if reflux and nausea are prominent, it is reasonable to think of this as a symptom needing review rather than simply a “fussy eating” problem.

Practical ways to make eating easier

Different things help different people, but these approaches are often more realistic than trying to push through large meals.

1. Think “little and often”

Many people do better with five or six small eating opportunities through the day instead of three big meals. That may mean a small breakfast, a mid-morning snack, a light lunch, a nourishing drink, an evening meal and a supper snack.

2. Lower the effort of eating

Soft, moist foods are often easier than dry, chewy or crumbly foods. Examples include:

  • porridge
  • yoghurt
  • custard or rice pudding
  • mashed potato with added butter or cheese
  • scrambled eggs
  • soup with cream or grated cheese
  • stews, casseroles or sauced dishes

3. Use drinks as nutrition

For some patients, drinks are easier to manage than food. Nourishing options can include:

  • milky drinks
  • smoothies
  • milkshakes
  • fortified hot drinks
  • commercial oral nutritional supplements if prescribed or advised

4. Rest before eating

If fatigue or breathlessness are major barriers, it can help to eat after a rest rather than after exertion. Some people find breakfast or lunch easier than an evening meal.

5. Sit upright and stay upright afterwards

This can be especially helpful when reflux, coughing or chest discomfort are part of the picture.

6. Slow the pace

It is acceptable to eat slowly and pause often. Some patients benefit from smaller mouthfuls and short breathing pauses between them.

7. Look for manageable variety

If the diet has become very narrow, widening it gently may be more successful than trying to overhaul everything at once.

How to support weight maintenance

When keeping weight on is difficult, the most useful approach is often to increase the energy and protein content of what is already being tolerated.

Food-first ideas

  • Add butter, cream, cheese, yoghurt, milk powder or olive oil to foods where suitable.
  • Choose full-fat products rather than “diet” versions if weight loss is a concern.
  • Add grated cheese to soup, mashed potato, scrambled eggs or vegetables.
  • Make porridge with milk rather than water.
  • Keep easy snacks available, such as yoghurts, cheese and crackers, peanut butter, hummus, custard, rice pudding or milky desserts.

Protein matters

Protein helps preserve muscle. Good sources include:

  • milk, yoghurt and cheese
  • eggs
  • meat, fish and poultry if tolerated
  • beans, lentils and other pulses
  • nut butters where suitable

Oral nutritional supplements

When food alone is not enough, a doctor or dietitian may suggest oral nutritional supplements. These are often used between meals rather than instead of meals. They can be particularly helpful when appetite is low or meal size is very limited.

In general UK nutrition practice, a “food first” approach is usually tried first where appropriate, but oral nutritional supplements are commonly used when someone is at higher risk of malnutrition or is unable to meet needs from food alone.

Food and medicine issues to remember

Food and medicine can interact in two main ways.

1. Medicines can affect eating

Antifungal treatment and other medicines may contribute to:

  • nausea
  • indigestion
  • altered taste
  • poor appetite
  • bowel upset

If these symptoms started after a medicine was introduced or changed, it is worth discussing that with the prescribing team.

2. Food can affect medicines

Some antifungal medicines have specific instructions about when to take them in relation to food. For example:

  • Itraconazole capsules are generally taken with or just after food, while itraconazole liquid is generally taken on an empty stomach.
  • Voriconazole is usually taken on an empty stomach.
  • Some medicines also have important interactions with antacids or acid-suppressing medicines.

Because formulations differ, and because other medicines may also interact, patients should follow the instructions they have been given for their exact preparation and check with a pharmacist or clinical team if unsure.

Grapefruit and other food interactions: some medicines have clinically important food interactions. Patients should check current advice for each medicine rather than relying on memory or online generalisations.

Common diet myths

Dairy always makes mucus worse

This is a very common belief. Current evidence does not show that dairy routinely increases lung mucus production for most people. Some people do notice a thicker mouth or throat feeling after milk, which may relate to texture rather than extra mucus. If dairy is well tolerated, it can be a useful source of calories and protein.

Sugar “feeds” aspergillosis, so it should be cut out completely

Patients often hear this online, but strict self-imposed restriction can be more harmful than helpful when someone is already struggling to maintain intake. For many patients with weight loss, the immediate nutritional priority is adequate calories and protein, not aggressive dietary exclusion.

There is a special anti-aspergillosis diet

There is no widely accepted specialist diet that treats aspergillosis itself. In routine practice, nutrition advice usually focuses on preventing or treating malnutrition, easing symptoms and managing medicine-related issues.

If eating is difficult, I should just avoid more foods

Sometimes a food really is hard to tolerate, but repeated restriction can shrink the diet too far. Often it is more useful to ask, “Can this be made easier to eat?” rather than “Should I cut this out altogether?”

When to seek medical help

Patients should speak to their doctor, specialist team or another qualified healthcare professional if they have any of the following:

  • ongoing unplanned weight loss
  • clothes, rings or dentures becoming looser
  • difficulty eating most days
  • a very narrow diet with only a few “safe” foods
  • persistent nausea, reflux, bloating or abdominal discomfort
  • increasing weakness or fatigue
  • concerns that medicines are worsening appetite or stomach symptoms

It may be appropriate to ask about a dietitian referral, especially if intake has been poor for some time or there are signs of malnutrition.

Seek urgent medical advice if:

  • food or fluids are being kept down very poorly
  • there are signs of dehydration
  • weight loss is rapid or severe
  • pain, vomiting, swallowing difficulty or other worrying symptoms are developing

Common questions

Should I force myself to eat full meals?

Usually not. If full meals are consistently overwhelming, smaller and more frequent intake is often more successful.

Are liquid calories “cheating”?

No. For some people, nourishing drinks are one of the most practical ways to protect weight and strength.

What if I only manage a few foods?

That is still worth discussing. A restricted diet may be understandable, but it can increase nutritional risk over time.

What if dairy feels unpleasant?

Individual experience matters. If a food clearly feels uncomfortable, it may help to try alternatives or use smaller amounts in different forms. But many people do not need to exclude dairy automatically.

Could reflux be making my cough worse?

Yes, it can in some people. Reflux can irritate the upper airway and may contribute to cough or discomfort around meals.

When to seek medical advice

Ask for medical advice if you are losing weight, struggling to eat most days, developing a very restricted diet, or think nausea, reflux or medication side effects are affecting your intake. Ask urgently if you are becoming dehydrated, vomiting repeatedly, or your intake has become extremely poor.

Author and review information

Prepared for: aspergillosis.org

Purpose: general educational information for patients and non-specialists

Review note: Because medicine instructions can change between formulations and brands, patients should always check the current advice supplied with their own prescription and confirm uncertainties with a pharmacist or clinical team.

References and further reading

  1. Carter C, Muldoon EG, Kosmidis C. Chronic pulmonary aspergillosis - a guide for the general physician. 2024.
    PubMed
  2. Tashiro M, Takazono T, Izumikawa K. Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, diagnosis, treatment, and unresolved challenges. 2024.
    Free full text
  3. Roboubi A, et al. Allergic bronchopulmonary aspergillosis. 2023.
    PubMed
  4. Sunman B, et al. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. 2020.
    Free full text
  5. Madhavan V, et al. Malnutrition in allergic bronchopulmonary aspergillosis complicating asthma. 2023.
    Free full text
  6. British Dietetic Association. Spotting and treating malnutrition.
    BDA resource
  7. BAPEN. Food first / food enrichment.
    BAPEN resource
  8. BAPEN / Malnutrition Pathway. Managing malnutrition in COPD.
    PDF
  9. NICE. Managing malnutrition in COPD, The Malnutrition Pathway.
    NICE shared learning resource
  10. NHS. Heartburn and acid reflux.
    NHS advice
  11. Cambridge University Hospitals NHS Foundation Trust. Dietary and lifestyle advice for adults with gastro-oesophageal reflux disease (GORD).
    CUH advice
  12. NICE BNF. Itraconazole.
    BNF drug monograph
  13. Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Itraconazole.
    PDF
  14. Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Voriconazole.
    PDF
  15. Oxford University Hospitals NHS Foundation Trust. Advice about antifungals.
    PDF
  16. Balfour-Lynn IM. Milk, mucus and myths. Archives of Disease in Childhood. 2019.
    Article
  17. Pinnock CB, Graham NM, Mylvaganam A. Relationship between milk intake and mucus production in adult volunteers challenged with rhinovirus-2. 1990.
    PubMed
  18. ASCIA. Milk, mucus and cough.
    Patient resource

Cystic Fibrosis, CFTR Gene Variants, and Aspergillosis

Last reviewed: 8 April 2026

Some people with aspergillosis are told they have cystic fibrosis (CF), or that they carry a CFTR gene variant. This can be unexpected and may raise concerns about whether this explains their symptoms or diagnosis.

This article explains how cystic fibrosis and CFTR gene variants relate to Aspergillus-related lung disease, what current research shows, and—importantly—what conclusions should not be drawn.

Contents


Key points

  • Most people with aspergillosis do not have cystic fibrosis.
  • Most people with cystic fibrosis do not develop ABPA or CPA.
  • ABPA is linked to mucus and immune responses, not just infection.
  • CFTR variants may contribute to risk in some people, but are usually only one factor.
  • CPA is mainly driven by structural lung damage, not CFTR genetics.

Back to top ↑


Important reassurance

Most people with aspergillosis do not have cystic fibrosis, and most people with cystic fibrosis do not develop Aspergillus-related disease.

Although these conditions can overlap, they are usually separate. Genetic findings such as CFTR variants should be interpreted carefully and in context.

Back to top ↑


What is cystic fibrosis?

Cystic fibrosis is a genetic condition caused by changes in the CFTR gene. This gene regulates salt and water movement across cells.

When CFTR function is reduced:

  • mucus becomes thick and sticky
  • airways are harder to clear
  • microorganisms persist more easily

This creates an environment where bacteria and fungi can accumulate over time.

Back to top ↑


What is a CFTR gene variant?

CFTR variants range from severe mutations (causing cystic fibrosis) to mild or uncertain variants.

Carriers (with one variant):

  • are common in the general population
  • usually have no symptoms
  • may have subtle effects in some cases

These subtle effects may include reduced mucus clearance or increased susceptibility to airway inflammation.

Back to top ↑


How CFTR affects the lungs

CFTR dysfunction affects the lungs in several key ways:

  • Mucus dehydration: mucus becomes thick and difficult to clear
  • Impaired clearance: particles and microbes remain in the airways
  • Chronic inflammation: immune responses become exaggerated

This combination creates a “retention environment” where inhaled organisms—including Aspergillus—may persist.

Back to top ↑


How Aspergillus behaves in the lungs

Aspergillus is inhaled by everyone, but its effects vary depending on the lung environment.

  • Healthy lungs: spores are cleared
  • Impaired clearance: spores may persist
  • Sensitive immune system: allergic reactions may develop
  • Damaged lungs: chronic infection may develop

This explains why Aspergillus-related disease is diverse and depends heavily on underlying lung conditions.

Back to top ↑


ABPA and cystic fibrosis

ABPA is an allergic immune reaction to Aspergillus.

It is recognised in cystic fibrosis because:

  • mucus retention increases exposure to Aspergillus
  • immune responses can be exaggerated

However:

  • Many CF patients never develop ABPA
  • Most ABPA patients do not have CF

Some studies suggest CFTR variants may increase susceptibility, but this is not consistent across all research.

Key message: ABPA and CF can overlap, but one does not imply the other.

Back to top ↑


CPA and cystic fibrosis

CPA is a chronic fungal infection that develops in structurally damaged lungs.

The most important risk factor is:

pre-existing lung damage

This includes:

  • bronchiectasis
  • previous tuberculosis
  • COPD

Cystic fibrosis can lead to bronchiectasis, and therefore indirectly increase CPA risk.

However:

  • CPA is rarely driven directly by CFTR genetics
  • most CPA patients do not have CF

Key message: CPA is primarily a disease of lung structure, not genetics.

Back to top ↑


Modern CF treatments and Aspergillus

CFTR modulators (such as elexacaftor/tezacaftor/ivacaftor) have transformed CF care.

They:

  • improve CFTR function
  • thin mucus
  • improve clearance

Studies suggest:

  • reduced Aspergillus detection in some patients
  • fewer ABPA exacerbations in some cases

However:

  • ABPA still occurs
  • existing lung damage remains
  • immune responses are not fully corrected

Overall: these therapies improve risk but do not eliminate Aspergillus-related disease.

Back to top ↑


Does a CFTR variant explain symptoms?

No single factor explains complex lung disease.

Symptoms may result from:

  • underlying lung disease
  • infection
  • inflammation
  • environmental exposure

A CFTR variant may contribute, but is rarely the sole cause.

Back to top ↑


What should patients take from this?

  • CF and CFTR variants can sometimes contribute
  • ABPA has the strongest connection
  • CPA is mainly driven by lung damage
  • Most patients with aspergillosis do not have CF

Back to top ↑


When to seek medical advice

Seek advice if symptoms worsen, change, or include coughing up blood, fever, or chest pain.

Back to top ↑


Conclusion

Cystic fibrosis and CFTR gene variants can play a role in some patients with Aspergillus-related lung disease, particularly where mucus clearance is affected. However, they should not be overemphasised. In most cases, they are just one part of a broader clinical picture involving lung structure, immune response, and environmental exposure.

Back to top ↑


References

This article is for general information and does not replace advice from your clinical team.


Weekly Aspergillosis Research Update: 31 March – 7 April 2026

This week’s research reinforces several consistent themes in aspergillosis: ongoing diagnostic confusion (particularly with tuberculosis and cancer), increasing movement toward precision medicine, and continued development of both antifungal therapies and biomarkers. There is also a growing emphasis on host-pathogen interactions rather than fungal burden alone.

Key Highlights

  • Isavuconazole levels can become unexpectedly high due to genetics and drug interactions.
  • Chronic pulmonary aspergillosis (CPA) can mimic lung cancer, risking delayed diagnosis.
  • New biomarker (EDN) for ABPA shows promise for diagnosis and monitoring.
  • Azole resistance research highlights differences between Aspergillus species.
  • New antifungal approaches emerging (olorofim, nitroxoline).
  • Host response is central – fibroblasts and immune pathways actively influence disease.
  • TB vs aspergillosis confusion persists in real-world settings.

Contents


Clinical & Diagnostic Studies

CPA mistaken for lung cancer

Paper: PubMed

A case report describes chronic pulmonary aspergillosis presenting as suspected lung malignancy in a patient with asthma and ABPA overlap.

Why this matters: CPA continues to be misdiagnosed due to tumour-like imaging appearances. This reinforces the need to consider fungal disease in patients with underlying lung conditions.

Invasive sinus aspergillosis causing bone destruction

Paper: Free full text

Granulomatous invasive aspergillosis led to facial bone destruction and neurological symptoms.

Why this matters: Delayed diagnosis of invasive disease can lead to severe structural damage. Early imaging and specialist input are critical.

Aspergillus infection in suspected TB patients

Paper: PubMed

Study shows overlap between tuberculosis and aspergillosis in symptomatic patients.

Why this matters: Persistent global issue—shared symptoms delay correct diagnosis and treatment, particularly relevant for CPA pathways.

Invasive aspergillosis in critical illness

Paper: PubMed

Case of invasive pulmonary aspergillosis in a patient with severe viral illness.

Why this matters: Reinforces that aspergillosis is not limited to traditional risk groups and can complicate severe systemic illness.


Treatment & Pharmacology

Isavuconazole toxicity linked to genetics

Paper: Free full text

Case report of supratherapeutic isavuconazole levels linked to CYP3A5 genotype and interacting medications.

Why this matters: Even “predictable” antifungals show variability. Supports therapeutic drug monitoring and future personalised dosing approaches.

Olorofim pharmacokinetics

Paper: PubMed

Study demonstrates tissue distribution of olorofim in preclinical models.

Why this matters: Supports ongoing development of a key next-generation antifungal, particularly for resistant disease.

Nitroxoline shows antifungal activity

Paper: PubMed

Repurposed drug demonstrates activity against Aspergillus via copper disruption and oxidative stress.

Why this matters: Highlights potential for non-azole antifungal strategies in future treatment.


Biology, Immunology & Resistance

Azole resistance and Aspergillus genomics

Paper: PubMed

Genomic study of Aspergillus section Fumigati explores resistance mechanisms and pathogenicity.

Why this matters: Different species may respond differently to antifungals—accurate identification is increasingly important.

Fibroblasts actively support lung defence

Paper: PubMed

Study shows fibroblasts contribute to immune defence and tissue repair during infection.

Why this matters: Disease outcomes depend on host response, not just fungal burden—important for future therapies.

Immune pathway targeting in fungal keratitis

Paper: PubMed

PIM1 inhibition reduces inflammation via STING pathway signalling.

Why this matters: Supports growing interest in targeting immune pathways alongside antifungal therapy.


Biomarkers & Diagnostics

Eosinophil-derived neurotoxin (EDN) in ABPA

Paper: PubMed

EDN proposed as a biomarker for allergic bronchopulmonary aspergillosis.

Why this matters: Could improve diagnosis and monitoring, helping distinguish ABPA from asthma or sensitisation alone.

Commentary on ISHAM ABPA guidelines

Paper: PubMed

Discussion of updated international guidance on ABPA diagnosis and management.

Why this matters: Highlights ongoing refinement of diagnostic criteria and classification systems.


Wider Context

Fungal extracellular vesicles

Paper: PubMed

Review of fungal vesicles in pathogenesis and host interaction.

Why this matters: Emerging area that may influence future diagnostics and therapies.

Aspergillosis in broader disease settings

  • Cystic fibrosis study: PubMed
  • Adenovirus meta-analysis: PubMed
  • Haematology correspondence: PubMed

Why this matters: Aspergillosis continues to appear across a wide range of conditions, particularly in critically ill or immunocompromised patients.


Overall Interpretation

This week’s literature reinforces several strategic priorities:

  • Earlier and more accurate diagnosis remains essential, particularly in distinguishing CPA from TB and cancer.
  • Precision medicine is advancing, with growing roles for pharmacogenomics, drug monitoring, and species-level identification.
  • New antifungal options are progressing, but remain largely in development.
  • Host response is increasingly recognised as central to disease progression and outcomes.

Overall, the field continues to move toward more personalised, biology-driven approaches to diagnosis and management.


Voriconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Voriconazole interacts with many medicines.
  • It affects several liver enzyme pathways, including CYP3A4, CYP2C19, and CYP2C9.
  • Its behaviour can vary more from one person to another than some other azoles.
  • Some medicines can make voriconazole stronger, while others can make it less effective.
  • Visual side effects and sensitivity to sunlight are well recognised with voriconazole.

What is voriconazole?

Voriconazole is an azole antifungal often used in serious fungal infections, including aspergillosis. It can be very effective, but it also has a relatively complex interaction profile.

Why voriconazole interacts with so many medicines

Voriconazole affects several liver enzyme systems, including CYP3A4, CYP2C19, and CYP2C9. It can increase the levels of some medicines, while some other medicines can lower voriconazole levels and reduce its effectiveness.

Because voriconazole metabolism varies between patients, the same combination can affect people differently.

The interaction groups most likely to matter

Steroids

Voriconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.

Medicines that reduce voriconazole levels

Some medicines, including certain anti-seizure medicines and rifampicin-type antibiotics, can reduce voriconazole levels so much that the antifungal may not work properly.

Blood thinners

Some blood thinners may become stronger when taken with voriconazole, increasing bleeding risk.

Heart rhythm medicines

Voriconazole can contribute to QT prolongation, so combinations with other medicines that affect heart rhythm may be particularly important.

Statins

Some statins can become stronger when taken with voriconazole, increasing the risk of muscle side effects.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly with voriconazole and often require specialist monitoring and dose adjustment.

Sedatives and some mental health medicines

Some sedatives and psychiatric medicines can become stronger when combined with voriconazole, increasing the risk of drowsiness, confusion, or other side effects.

Voriconazole-specific issues patients should know

Visual changes

Temporary visual disturbances are well recognised with voriconazole. Patients may notice blurred vision, brighter vision, or changes in colour perception.

Photosensitivity

Voriconazole can increase sensitivity to sunlight. Patients should use sensible sun protection and report new skin changes, especially during long-term treatment.

Variable drug levels

Voriconazole levels can vary between patients, which is one reason some teams use therapeutic drug monitoring in selected situations.

What patients should do in practice

  • Tell your clinical team and pharmacist that you are taking voriconazole.
  • Check before starting new medicines, including over-the-counter or herbal products.
  • Report visual changes, significant sensitivity to sunlight, or a change in symptoms after a medicine change.
  • Do not change treatment without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, severe palpitations, marked confusion, or rapid worsening after a medicine change.

Important

This page is educational and does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Itraconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Itraconazole can interact with many other medicines.
  • It usually does this by affecting liver enzymes, especially CYP3A4.
  • Some combinations need careful monitoring, while others are best avoided.
  • Capsules and liquid formulations are not handled by the body in exactly the same way.
  • This page highlights the interactions most likely to matter to people with aspergillosis.

What is itraconazole?

Itraconazole is an azole antifungal used in aspergillosis and other fungal infections. It has a relatively high interaction burden, so medicine checks are especially important before starting it and whenever another medicine is added, stopped, or changed.

Why itraconazole interacts with so many medicines

Itraconazole can increase the levels of some other medicines by affecting liver enzymes, especially CYP3A4. This means that some medicines may become stronger than intended, which can increase the risk of side effects or toxicity.

The interaction groups most likely to matter

Steroids and inhalers

This is one of the most important groups for many aspergillosis patients, especially those with asthma or allergic bronchopulmonary aspergillosis. Itraconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.

Possible symptoms to report: unusual weight gain, easy bruising, increased facial rounding, mood changes, worsening blood sugar control, weakness, or marked fatigue.

Statins

Some statins can become much stronger when taken with itraconazole. This can increase the risk of muscle toxicity.

Possible symptoms to report: new muscle pain, muscle weakness, or dark urine.

Blood thinners

Itraconazole can increase the effect of some blood thinners, which may raise bleeding risk.

Possible symptoms to report: unusual bruising, bleeding that is hard to stop, black stools, vomiting blood, or coughing up much more blood than usual.

Heart and rhythm medicines

Some combinations can increase the risk of serious heart rhythm problems. Itraconazole is also used cautiously in people with a history of ventricular dysfunction or heart failure unless the infection is serious.

Possible symptoms to report: fainting, palpitations, marked dizziness, increasing ankle swelling, or worsening breathlessness.

Sleeping tablets, sedatives, and some mental health medicines

Some sedatives and psychotropic medicines can become stronger when combined with itraconazole, increasing the risk of drowsiness, confusion, falls, or breathing problems.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly when taken with itraconazole and usually need specialist monitoring.

Medicines that can make itraconazole less effective

Some medicines lower itraconazole levels, which means the antifungal may not work as well. This can happen with some anti-seizure medicines, rifampicin-type antibiotics, and some antiviral medicines.

Acid-reducing medicines and itraconazole capsules

Reduced stomach acid can lower the absorption of itraconazole capsules. This means reflux medicines, antacids, and some acid-suppressing treatments can affect how well the capsules work. The liquid formulation behaves differently and should not be treated as interchangeable with capsules.

What patients should do in practice

  • Keep a current medicines list and bring it to appointments.
  • Tell clinicians and pharmacists if you are taking itraconazole.
  • Ask specifically about inhalers, steroid tablets, statins, blood thinners, and reflux treatment.
  • Do not change doses or stop medicines without advice.
  • If your itraconazole formulation changes, ask whether it should be taken with food or on an empty stomach.

When to seek medical advice

Seek urgent medical advice for severe bleeding, black stools, vomiting blood, severe muscle pain, fainting, marked palpitations, or rapidly worsening breathlessness.

Important

This page is not a full interaction database. For a complete medicine-by-medicine check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Amphotericin B interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Amphotericin B comes in different formulations, and they are not interchangeable.
  • Its main interaction risks are different from the azoles.
  • The most important problems are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines.
  • These risks matter most with intravenous treatment.
  • If you hear “amphotericin B”, it is important to know which formulation is being used.

What is amphotericin B?

Amphotericin B is an antifungal used mainly for serious fungal infections. In modern UK practice this often means liposomal amphotericin B, but conventional amphotericin B deoxycholate is also a recognised formulation.

Why amphotericin B interactions are different from azoles

Unlike azole antifungals, amphotericin B does not mainly cause medicine interactions through liver enzymes. Its most important interaction risks usually relate to kidney injury, low potassium, low magnesium, and infusion-related effects.

The interaction groups most likely to matter

Other medicines that can damage the kidneys

This is one of the most important groups. Combining amphotericin B with other nephrotoxic medicines can increase the risk of kidney injury.

Diuretics, steroids, and other medicines that lower potassium

Amphotericin B can lower potassium, and some other medicines can make this worse. This may increase the risk of weakness, cramps, or heart rhythm problems.

Digoxin and heart-rhythm-sensitive situations

Low potassium caused by amphotericin B can make digoxin-related toxicity more likely and may increase the importance of electrolyte monitoring.

Flucytosine

When combined with flucytosine, specialist monitoring may be needed because toxicity can increase.

Some cancer medicines and intensive hospital treatments

In hospital, additive toxicity with other intensive treatments may be particularly important, especially where kidneys and electrolytes are already under strain.

White blood cell transfusions

Acute lung reactions are a recognised specialist concern if amphotericin B is given during or soon after leukocyte transfusions.

Why the formulations matter

Amphotericin B formulations are not interchangeable. Conventional amphotericin B deoxycholate and liposomal amphotericin B have different dosing, different handling by the body, and different safety profiles. Using the wrong formulation in the wrong dose has caused serious and even fatal errors.

In general, liposomal amphotericin B is less nephrotoxic than conventional amphotericin B deoxycholate, but it still requires careful monitoring.

What patients should do in practice

  • Ask which amphotericin B formulation is being used.
  • Tell the clinical team about all medicines, especially kidney-risk medicines, diuretics, steroids, and digoxin.
  • Expect blood tests to monitor kidney function, potassium, and magnesium during intravenous treatment.
  • Report weakness, reduced urine output, worsening swelling, palpitations, or marked dizziness.

When to seek medical advice

Seek urgent medical help for severe breathlessness, fainting, major palpitations, or a rapid deterioration during treatment.

Important

This page is educational and does not list every possible interaction. Amphotericin B treatment is usually managed by specialist teams, especially when given intravenously.

References


Isavuconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Isavuconazole can interact with other medicines, but its interaction profile is often less complex than older azoles.
  • It mainly interacts through CYP3A4.
  • Some medicines can increase isavuconazole levels, while others can reduce its effectiveness.
  • It has an important difference from some other azoles: it can shorten the QT interval.
  • It is still essential to check new medicines carefully.

What is isavuconazole?

Isavuconazole is a newer azole antifungal used in invasive aspergillosis and some other serious fungal infections. It is often seen as having a more predictable interaction profile than some older azoles, but it still has important interactions.

Why isavuconazole interacts with other medicines

Isavuconazole is mainly linked to CYP3A4. This means some medicines can become stronger when combined with it, while other medicines can lower isavuconazole levels and reduce its effectiveness.

The interaction groups most likely to matter

Medicines that reduce isavuconazole effectiveness

Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower isavuconazole levels and may make treatment ineffective.

Steroids

Some steroid levels may rise with isavuconazole, although the interaction pattern is often less intense than with some older azoles.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin may increase and usually need specialist review and monitoring.

Blood thinners

Some blood thinners may become stronger, increasing bleeding risk.

Statins

Some statin levels may increase, which can raise the risk of muscle side effects.

Important isavuconazole-specific points

QT shortening

Unlike several other azole antifungals, isavuconazole can shorten the QT interval. This is an important difference and should be considered when other heart medicines are being reviewed.

Generally simpler interaction profile

Compared with itraconazole and voriconazole, isavuconazole is often considered a little easier to manage in patients taking several medicines, although checks are still essential.

What patients should do in practice

  • Tell your pharmacist or clinician if you are taking isavuconazole.
  • Check before starting prescription, over-the-counter, or herbal medicines.
  • Ask specifically about anti-seizure drugs, antibiotics, blood thinners, and heart medicines.
  • Do not stop or change medicines without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, severe palpitations, severe muscle pain, or rapid worsening after a medicine change.

Important

This page is educational and not a complete interaction database. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References